WuXi Collaboration with Israeli Partners
The Future of Cancer Therapy: An Interview with Yinon Ben-Neriah, Hebrew University

WuXi News
Dr. Ge Li Receives Executive of the Year Award from SCRIP
Over 1,100 Executives Signed-up for 4th Annual WuXi Global Forum at J.P. Morgan Conference
WuXi Healthcare Ventures Joins Financing Rounds for Twist Bioscience and Syros Pharmaceuticals
 
WuXi Plans $120 Million Investment in New Integrated Biologics Solution Center to Expedite Biologics Development from Ideas to Clinic
WuXi and MedImmune Form a Strategic Alliance to Develop Innovative Biologics in China for AstraZeneca
WuXi Healthcare Ventures II Closes with Oversubscription
WuXi Congratulates MSD on Receiving FDA Approval of ZEPATIER™
Congratulations to Chia Tai Tianqing Pharmaceutical Group and Janssen for Licensing Agreement
Perspectives
Combining Service and Investment: An Interview with Wei Li, Co-Founder of WuXi Healthcare Ventures
Developing a Novel ADC for Global Market via Innovative Three-party Collaboration - An Interview with Dr. Jiawen Han, Vice President, WuXi Biologics

Meet IDSU Leadership: An Interview with Tao Guo, VP of Medicinal Chemistry
In This Issue
 
Industry Beats
TAU links growth factor to development of Alzheimer's disease (Source: Tel Aviv University)

BioLight Reports Positive Second Clinical Study Results for its TeaRx Multi-Assay Test for Dry Eye Syndrome (Source: PR Newswire)

Israeli Pharma Firm to Develop Alternative to Viagra (Source: The Times of Israel)

Israeli Researchers Develop Novel Method To Treat Aggressive Blood Cancers (Source: No Camels)

Breakthrough Israeli Research Improves HIV/AIDS Treatment, Could Lead To Cure (Source: No Camels)

CollPlant Reports Positive Interim Trial Results for Vergenix, Indicated for the Treatment of Tendinopathy (Source: CollPlant)

Can-Fite Announces 2016 Clinical Milestones for its Pipeline of Drugs in Six Indications (Source: Can-Fite)

Compugen Achieves Third Preclinical Milestone in Cancer Immunotherapy Collaboration with Bayer (Source: Compugen)

Kamada's Human Rabies Immune Globulin Successfully Meets Primary Endpoint in U.S. Pivotal Phase 2/3 Clinical Trial as a Post-Exposure Treatment (Source: Kamada)

Teva Announces Launch of Generic Ortho Tri-Cyclen® Lo in the United States (Source: Teva Pharmaceuticals)

Kite Pharma Expands Its Clinical and Research Partnership With the National Cancer Institute (NCI) for Next-Generation CAR Programs to Treat B-Cell Malignancies (Source: Kite Pharma)

BioLineRx Announces Collaboration with MSD to investigate the combination of KEYTRUDA (pembrolizumab) and BL-8040 in Pancreatic Cancer (Source: BioLineRx) 

Sanara Ventures Cements Teva-Philips Ties (Source: Sanara Ventures)

J&J Backs Israeli Startup in $28M Round for Heart Failure Implant (Source: Fierce Medical Device)

Phillip Morris Invests $20m in Syqe Cannabis Inhaler (Source: iCAN)

Takeda Provides Further Information about its New Business Venture with Teva (Source: Takeda) 

Adicet Bio Announces Closing of $51 Million Series A Financing and Acquisition of Applied Immune Technologies (Source: PR Newswire)

CartiHeal Raises $15 Million (Source: PR Newswire)

Insightec Secures $22 Million and Appoints Maurice R. Ferre, MD, as CEO (Source: Insightec)

Israeli Catheter Co Pi-Cardia Raises $10m (Source: Globes)

KAHR Medical Reports Raising $12M At First Closing Of Its Series B Private Equity Financing (Source: KAHR Medical)
Drug Approvals & Designations


Upcoming Events
February 22-23, 2016
Tel Aviv University, Tel Aviv

March 9, 2016
Independence Park, Tel Aviv

March 29, 2016
The Hebrew University of Jerusalem, Jerusalem
Follow us on Twitter View our profile on LinkedIn